Novo Nordisk Hopes Victoza's EU Clearance Bodes Well For U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
GLP-1 inhibitor approved in Europe without restrictions on use, but Novo Nordisk will conduct a five-year cardiovascular outcomes trial.